Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment

Patent metadata

Field	Value
Publication number	US-11299543-B2
Application number	US-201716306282-A
Country	US
Kind code	B2
Filing date	Jun 1, 2017
Priority date	Jun 2, 2016
Publication date	Apr 12, 2022
Grant date	Apr 12, 2022

Abstract

This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.

First claim

What is claimed is:

1. A method of treating a human subject afflicted with a Hodgkin lymphoma, comprising:
(a) administering to the human subject about 3 mg/kg of an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 receptor (PD-1) and inhibits PD-1 activity (anti-PD-1 antibody) once every three weeks; and
(b) administering to the human subject about 1.8 mg/kg of brentuximab vedotin once every three weeks;
wherein (i) brentuximab vedotin is administered to the human subject on day 1 of a first 21-day cycle; and
(ii) the anti-PD-1 antibody is administered to the human subject on day 8 of the first 21-day cycle;
wherein a combination of brentuximab vedotin and the anti-PD-1 antibody is administered on day 1 of each of a second 21-day cycle, a third 21-day cycle; and a fourth 21-day cycle, wherein the second 21-day cycle, the third 21-day cycle, and the fourth 21-day cycle follow in succession after the first 21-day cycle; and
wherein the Hodgkin lymphoma comprises one or more cells that express CD30.

2. The method of claim 1 , wherein the Hodgkin lymphoma is classical Hodgkin lymphoma (cHL).

3. The method of claim 1 , wherein at least about 0.1% of the Hodgkin lymphoma cells express CD30.

4. The method of claim 1 , wherein at least about 5% of the Hodgkin lymphoma cells express CD30.

5. The method of claim 1 , wherein the anti-PD-1 antibody comprises nivolumab.

6. The method of claim 1 , wherein the Hodgkin lymphoma comprises one or more cells that express PD-L1, PD-L2, or both PD-L1 and PD-L2.

7. The method of claim 1 , wherein the human subject exhibits progression-free survival of at least about one month after the initial administration of the anti-PD-1 antibody and/or brentuximab vedotin.

8. The method of claim 1 , wherein the Hodgkin lymphoma is relapsed Hodgkin lymphoma or refractory Hodgkin lymphoma.

9. The method of claim 8 , wherein the relapsed Hodgkin lymphoma is relapsed Hodgkin lymphoma after autologous stem cell transplant (ASCT) or relapsed Hodgkin lymphoma in a human subject ineligible for ASCT.

10. The method of claim 1 , wherein the anti-PD-1 antibody comprises pembrolizumab.

Assignees

• Bristol Myers Squibb Co
• Seattle Genetics Inc
• Seattle Genetics Tnc

Inventors

• Farsaci Benedetto
• Josephson Neil
• Cao Anthony
• Heiser Ryan

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C07K16/2818 Primary

  against CD28 or CD152 · CPC title

• C07K16/2878

  against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title